Found 7 matching trials
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity PHASE3 This pivotal, phase 3 study is designed to confirm the efficacy and safety ...
Show More Learn More & Join Trial
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants PHASE4 This was a double-blind, randomized, placebo- and positive-controlled, para...
Show More Location
Parexel Early Phase Clinical Unit (Los Angeles)
Learn More & Join Trial
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) PHASE2 The investigators plan to test the efficacy and safey of 6-months of open-l...
Show More Status
Enrolling By Invitation
Location
Massachusetts General Hospital
Learn More & Join Trial
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway PHASE3 A trial to compare the weekly and daily formulations of setmelanotide in pa...
Show More Location
Honor Health Research Institute
Learn More & Join Trial
Effects of RM-493 on Energy Expenditure in Obese Individuals PHASE1 Background:
\- RM-493 is a drug that stimulates parts of the brain that co...
Show More Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Learn More & Join Trial
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity PHASE3 This is a phase 3 open-label, clinical study to evaluate the efficacy, safe...
Show More Location
Children's Hospital Colorado
Learn More & Join Trial
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers PHASE1 The purpose of this study is to evaluate the multiple dose safety and toler...
Show More Location
Multiple Locations
Learn More & Join Trial